The daily administration of CBD (cannabidiol) as an adjunctive therapy mitigates psychotic symptoms in patients with schizophrenia, according to clinical trial data published online ahead of print in The American Journal of Psychiatry.
Two new studies published online today in JAMA (Journal of the American Medical Association) Psychiatry provide little support for previous claims that cannabis exposure is significantly harmful to the developing brain.
Last week, in what is becoming a semi-annual mainstream media ritual, news outlets around the globe published sensational headlines alleging that consuming cannabis will drives people crazy.
Cananbidiol (CBD), a non-psychotropic cannabinoid, alleviates psychotic symptoms and may hold promise as an alternative antipsychotic treatment, according to a review published in the November issue of the journal Neuropsychopharmacology.
[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To have NORML’s news alerts and legislative advisories delivered straight to your in-box, sign up here.] The use of cannabis is associated with lower mortality risk in patients with schizophrenia and related psychotic disorders, according to a forthcoming study to be published in the Journal of Psychiatric Research. (Read the abstract of the study online here.) An international team of investigators from the University of Maryland School of Medicine and Inje University in South Korea assessed […]
Every Wednesday on NORML SHOW LIVE, Dr. Mitch Earleywine joins us to discuss the latest research in cannabis and to take live calls and chat questions from listeners on marijuana culture, history, medicine, and science. Ã‚Â He is a member of the NORML Advisory Board and his research has been published in over fifty scientific journals […]